A Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies

NCT04865458 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Stopped Adjustment to the sponsor's development strategy

Conditions

Relapsed or Refractory B-cell Hematologic Malignancies

Interventions

DRUG: HEC89736

Sponsor

Sunshine Lake Pharma Co., Ltd.